ClinPGx Blog (Page 42)

Sign in Subscribe

More issues

New Pathway for Abacavir

We have posted a new pathway on PharmGKB summarizing the pharmacokinetics, pharmacodynamics and pharmacogenetics of abacavir. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) pro-drug, used for treating human immunodeficiency virus (HIV) infection. Abacavir is converted through several enzymatic steps into its active form, carbovir 5’-triphosphate (CBV-TP)

Update to CYP2C19 TPP lookup table

We have verified that position rs3758581 in CYP2C19*1 is allele A. The CYP2C19 TPP lookup table has been updated accordingly. View CYP2C19 haplotypes.

CPIC publishes guidelines for HLA-B*15:02 Genotype and Carbamazepine Use

The Clinical Pharmacogenomics Implementation Consortium (CPIC) has published guidelines for the use of genetic test results for HLA-B*15:02 and carbamazepine in Clinical Pharmacology and Therapeutics. In cases where a patient is known to carry at least one HLA-B*15:02 allele, the guideline recommends that the

Tacrolimus/Cyclosporine Pathways, Pharmacokinetics and Pharmacodynamics

We have added two new pathways to our collection, in collaboration with Dr. Christine Staatz from the University of Queensland and Dr. Raman Venkataramanan from the University of Pittsburgh. These pathways cover the pharmacokinetics and pharmacodynamics of tacrolimus and cyclosporine. Both drugs are immunosuppressants given to solid organ transplant recipients

Novel SNP in CYP2C cluster associated with warfarin dose in African Americans

The International Warfarin Pharmacogenetics Consortium (IWPC), which involves investigators from eight institutions including Stanford University, has identified a SNP that is associated with warfarin dose requirement in the African American population. As described in Lancet, rs12777823, located in the CYP2C cluster, shows an effect in African Americans that is independent

New VIP Summary for CYP2C8

A new VIP summary is available for CYP2C8, a member of the cytochrome P450 family of drug metabolizing enzymes. CYP2C8 accounts for 7% of CYP content in the liver, and is expressed to a lesser extent in the kidney, adrenal gland, mammary gland, brain, ovary, uterus, and duodenum. CYP2C8 plays

CPIC guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 Update

The 2013 update of the CPICguidelines for CYP2C19 and clopidogrel dosing is now available online, as an accepted article preview. This updated guideline refines the recommendations for specific CYP2C19alleles, with emphasis on the appropriate indication for CYP2C19genotype-directed antiplatelet therapy, and, an expanded literature review to include recent published evidence.

Big Data in Biomedicine

PharmGKB Developers and Curators attended the Big Data in Biomedicine conference this week, organized by Stanford University and the University of Oxford. The talks and panels raised a plethora of issues surrounding storing, sharing, analyzing, validating, visualizing and utilizing Big Data for improving healthcare and to drive change. Among the

New name for IL28B gene = IFNL3

PharmGKB has updated our gene names that comply with The Human Genome Nomenclature Committee (HGNC) approved symbol, approved name, and synonyms. One particular name change we would like to highlight with this update: The HGNC-approved gene symbol for IL28B is now IFNL3 (interferon lambda 3) - a gene with variants

Curators' Favorite Papers

The current Curators' Favorite Papers' highlights the higher frequency of genetic variants conferring increased risk for adverse drug reactions (ADRs) for many commonly used drugs in persons of African descent. Differences in drug response, cure rates and survival outcomes between different ethnic populations exist. To assess this, Aminkeng